Kura Oncology to Participate in Upcoming Investor Conference
Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the UBS Virtual Oncology Day.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kura Oncology (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the UBS Virtual Oncology Day. The management presentation is scheduled for October 1, 2025, at 2:30 p.m. ET.
Investors can access the live audio webcast through the Investors section of Kura's website, with a replay available after the event.
Details
News Market Reaction – KURA
On Sep 24, the day this news came out, KURA closed 1.70% above the previous close.
Data tracked by StockTitan Argus for the Sep 24 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference.
UBS Virtual Oncology Day
Wednesday, October 1, 2025
2:30 p.m. ET / 11:30 a.m. PT
A live audio webcast will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with an archived replay available following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors and media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.